Concepedia

Deepti Aurora-Garg

DA

Statistics

Publications

24

Citations

4.5K

H-Index

21

Active since

2016

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Yonsei University

Yale Cancer Center

Fondazione IRCCS Istituto Nazionale dei Tumori

Seoul National University

Deepti Aurora-Garg is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, oncology, and pembrolizumab therapy.

Publications per year

2016–2023

24

Publications

24

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

Aurélien Marabelle, Marwan Fakih, Juanita Lopez et al. · The Lancet Oncology · 2020 · 2.5K citations · Full text

, , +17

Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012

Ranee Mehra, Tanguy Y. Seiwert, Shilpa Gupta et al. · British Journal of Cancer · 2018 · 456 citations · Full text

, , +2

Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors

Răzvan Cristescu, Deepti Aurora-Garg, Andrew Albright et al. · Journal for ImmunoTherapy of Cancer · 2022 · 161 citations · Full text

, , +17

Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer

Kenneth Emancipator, Lingkang Huang, Deepti Aurora-Garg et al. · Modern Pathology · 2020 · 109 citations · Full text

, , +13

Association of tumour mutational burden with outcomes in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158

Aurélien Marabelle, Marwan Fakih, Juanita Lopez et al. · Annals of Oncology · 2019 · 106 citations · Full text

, , +14

1–5 of 24